Sangamo Therapeutics - SGMO Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $4.68
  • Forecasted Upside: 296.19%
  • Number of Analysts: 7
  • Breakdown:
  • 1 Sell Ratings
  • 3 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$1.18
▼ -0.2 (-14.49%)

This chart shows the closing price for SGMO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Sangamo Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SGMO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SGMO

Analyst Price Target is $4.68
▲ +296.19% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Sangamo Therapeutics in the last 3 months. The average price target is $4.68, with a high forecast of $10.00 and a low forecast of $1.00. The average price target represents a 296.19% upside from the last price of $1.18.

This chart shows the closing price for SGMO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 7 polled investment analysts is to hold stock in Sangamo Therapeutics. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 1 sell ratings
8/29/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 1 sell ratings
11/27/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 1 sell ratings
2/25/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 1 sell ratings
5/26/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 1 sell ratings
8/24/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 1 sell ratings
11/22/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 1 sell ratings
1/21/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 1 sell ratings
2/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/12/2024HC WainwrightReiterated RatingBuy ➝ Buy$3.00Low
2/6/2024HC WainwrightReiterated RatingBuy ➝ Buy$3.00Low
1/19/2024HC WainwrightReiterated RatingBuy ➝ Buy$3.00Low
11/7/2023Truist FinancialReiterated RatingBuy ➝ HoldLow
11/6/2023HC WainwrightLower TargetBuy ➝ Buy$5.00 ➝ $3.00Low
11/6/2023Wells Fargo & CompanyReiterated RatingOverweight ➝ Equal Weight$1.00Low
11/3/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Sector Perform$6.00 ➝ $2.00N/A
8/15/2023Truist FinancialLower TargetBuy ➝ Buy$8.00 ➝ $7.00Low
8/14/2023HC WainwrightReiterated RatingBuy ➝ Buy$5.00Low
8/11/2023WedbushLower TargetOutperform ➝ Outperform$16.00 ➝ $10.00Low
8/10/2023Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$5.00 ➝ $4.00Low
8/9/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$8.00 ➝ $6.00Low
8/9/2023BarclaysLower TargetOverweight ➝ Overweight$11.00 ➝ $9.00Low
5/10/2023Truist FinancialLower Target$16.00 ➝ $8.00Low
5/1/2023HC WainwrightLower Target$15.00 ➝ $5.00Low
4/28/2023Stifel NicolausLower Target$4.20 ➝ $3.90Low
4/28/2023Bank of AmericaDowngradeNeutral ➝ Underperform$5.00 ➝ $1.50Low
3/3/2023HC WainwrightLower TargetBuy$25.00 ➝ $15.00Low
2/27/2023WedbushUpgradeNeutral ➝ Outperform$16.00Low
2/23/2023Royal Bank of CanadaLower TargetOutperform$22.00 ➝ $13.00Low
1/6/2023Bank of AmericaDowngradeBuy ➝ Neutral$8.00 ➝ $5.00Low
1/4/2023Wells Fargo & CompanyLower TargetOverweight$20.00 ➝ $15.00Low
11/7/2022Wells Fargo & CompanyLower TargetOverweight$22.00 ➝ $20.00Low
6/13/2022WedbushReiterated RatingNeutral$5.00Medium
5/6/2022WedbushReiterated RatingNeutralHigh
4/5/2022Truist FinancialLower TargetBuy$23.00 ➝ $19.00Low
2/27/2022WedbushReiterated RatingHold$10.00Medium
1/7/2022WedbushReiterated RatingHold$10.00High
1/6/2022Stifel NicolausLower TargetHold ➝ Hold$9.00 ➝ $6.00High
8/26/2021HC WainwrightInitiated CoverageBuy$25.00Medium
5/3/2021Royal Bank of CanadaInitiated CoverageOutperform$22.00High
3/3/2021Wells Fargo & CompanyLower TargetOverweight$36.00 ➝ $29.00High
1/5/2021Stifel NicolausInitiated CoverageHold$16.00N/A
12/16/2020HC WainwrightReiterated RatingBuy$25.00Low
9/8/2020Bank of AmericaInitiated CoverageBuy$20.00Low
7/7/2020SunTrust BanksInitiated CoverageBuyHigh
6/22/2020HC WainwrightLower TargetBuy$16.00 ➝ $14.00Medium
6/19/2020WedbushReiterated RatingHold$11.00Medium
6/10/2020WedbushReiterated RatingHold$11.00High
3/4/2020WedbushReiterated RatingHold$10.00High
3/2/2020HC WainwrightReiterated RatingBuy$16.00High
12/23/2019HC WainwrightReiterated RatingBuy$16.00High
12/18/2019WedbushReiterated RatingHold$11.00Medium
12/11/2019WedbushReiterated RatingHold$11.00Low
12/9/2019CowenReiterated RatingBuyHigh
11/12/2019WedbushReiterated RatingHold$11.00Low
8/26/2019HC WainwrightInitiated CoverageBuy$16.00Medium
7/8/2019WedbushSet TargetHold$11.00Medium
6/23/2019WedbushSet TargetHold$11.00Medium
5/14/2019WedbushSet TargetHold$11.00Medium
3/10/2019WedbushSet TargetHold$10.00Medium
(Data available from 2/21/2019 forward)

News Sentiment Rating

0.80 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/25/2023
  • 3 very positive mentions
  • 7 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
8/24/2023
  • 3 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/23/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/23/2023
  • 1 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/22/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/22/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/21/2024
  • 5 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/20/2024

Current Sentiment

  • 5 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Sangamo Therapeutics logo
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.
Read More

Today's Range

Now: $1.18
Low: $1.15
High: $1.37

50 Day Range

MA: $0.56
Low: $0.36
High: $1.38

52 Week Range

Now: $1.18
Low: $0.29
High: $3.32

Volume

5,533,469 shs

Average Volume

2,791,580 shs

Market Capitalization

$209.27 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.04

Frequently Asked Questions

What sell-side analysts currently cover shares of Sangamo Therapeutics?

The following equities research analysts have issued research reports on Sangamo Therapeutics in the last twelve months: Bank of America Co., Barclays PLC, HC Wainwright, Royal Bank of Canada, Stifel Nicolaus, StockNews.com, Truist Financial Co., Wedbush, and Wells Fargo & Company.
View the latest analyst ratings for SGMO.

What is the current price target for Sangamo Therapeutics?

8 Wall Street analysts have set twelve-month price targets for Sangamo Therapeutics in the last year. Their average twelve-month price target is $4.68, suggesting a possible upside of 296.2%. Wedbush has the highest price target set, predicting SGMO will reach $10.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $1.00 for Sangamo Therapeutics in the next year.
View the latest price targets for SGMO.

What is the current consensus analyst rating for Sangamo Therapeutics?

Sangamo Therapeutics currently has 1 sell rating, 3 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in SGMO, but not buy more shares or sell existing shares.
View the latest ratings for SGMO.

What other companies compete with Sangamo Therapeutics?

Other companies that are similar to Sangamo Therapeutics include Curis, SAB Biotherapeutics, Agenus, Novavax and Elevation Oncology. Learn More about companies similar to Sangamo Therapeutics.

How do I contact Sangamo Therapeutics' investor relations team?

Sangamo Therapeutics' physical mailing address is 7000 MARINA BLVD, BRISBANE CA, 94005. The biopharmaceutical company's listed phone number is (510) 970-6000 and its investor relations email address is [email protected]. The official website for Sangamo Therapeutics is www.sangamo.com. Learn More about contacing Sangamo Therapeutics investor relations.